A new study has examined the effects of GLP-1 drugs on 175 different health outcomes. ​​​While these drugs have been found to ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Trump administration’s Centers for Medicare and Medicaid Services (CMS) has signaled that it will be revamping the ...

Weight loss drugs, such as those containing GLP-1 agonists like Wegovy and Mounjaro, have emerged as effective tools for people struggling to lose ...

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...